WO2016008401A8 - 一种含多西他赛的药物组合物 - Google Patents

一种含多西他赛的药物组合物 Download PDF

Info

Publication number
WO2016008401A8
WO2016008401A8 PCT/CN2015/083928 CN2015083928W WO2016008401A8 WO 2016008401 A8 WO2016008401 A8 WO 2016008401A8 CN 2015083928 W CN2015083928 W CN 2015083928W WO 2016008401 A8 WO2016008401 A8 WO 2016008401A8
Authority
WO
WIPO (PCT)
Prior art keywords
docetaxel
pharmaceutical composition
amino acid
carrier
polyethylene glycol
Prior art date
Application number
PCT/CN2015/083928
Other languages
English (en)
French (fr)
Other versions
WO2016008401A1 (zh
Inventor
滕鑫
Original Assignee
滕鑫
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410336415.6A external-priority patent/CN105287397A/zh
Priority claimed from CN201410336424.5A external-priority patent/CN105287398A/zh
Priority claimed from CN201410336464.XA external-priority patent/CN105310987A/zh
Priority claimed from CN201410336638.2A external-priority patent/CN105267158A/zh
Application filed by 滕鑫 filed Critical 滕鑫
Priority to US15/325,939 priority Critical patent/US10080720B2/en
Priority to GB1700560.4A priority patent/GB2542092B/en
Publication of WO2016008401A1 publication Critical patent/WO2016008401A1/zh
Priority to ZA2017/00278A priority patent/ZA201700278B/en
Publication of WO2016008401A8 publication Critical patent/WO2016008401A8/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

一种含多西他赛的药物组合物，由多西他赛和具有氨基酸端基的聚乙二醇甲醚-聚丙交酯嵌段共聚物所组成。其采用毒性更低的三嵌段共聚物为载体，除了药物有效成分和载体外不含其它添加物，其组分更简单、安全性更高，多西他赛含量可达20%以上。具有氨基酸端基的聚乙二醇甲醚-聚丙交酯嵌段共聚物与多西他赛形成的胶束，粒径较小，稳定性较高，且制剂中无需添加其它辅助成分，安全性更高，制备工艺简单易于工业应用。
PCT/CN2015/083928 2014-07-15 2015-07-14 一种含多西他赛的药物组合物 WO2016008401A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/325,939 US10080720B2 (en) 2014-07-15 2015-07-14 Pharmaceutical composition containing docetaxel
GB1700560.4A GB2542092B (en) 2014-07-15 2015-07-14 Polyethylene glycol methyl ether-polylactide-lysine micellar compositions comprising docetaxel
ZA2017/00278A ZA201700278B (en) 2014-07-15 2017-01-12 Pharmaceutical composition containing docetaxel

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN201410336415.6 2014-07-15
CN201410336415.6A CN105287397A (zh) 2014-07-15 2014-07-15 一种多西他赛的药物组合物
CN201410336424.5A CN105287398A (zh) 2014-07-15 2014-07-15 一种多西他赛的药物组合物
CN201410336464.XA CN105310987A (zh) 2014-07-15 2014-07-15 一种多西他赛的药物组合物
CN201410336638.2 2014-07-15
CN201410336638.2A CN105267158A (zh) 2014-07-15 2014-07-15 一种多西他赛的药物组合物
CN201410336464.X 2014-07-15
CN201410336424.5 2014-07-15

Publications (2)

Publication Number Publication Date
WO2016008401A1 WO2016008401A1 (zh) 2016-01-21
WO2016008401A8 true WO2016008401A8 (zh) 2019-01-10

Family

ID=55077914

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/083928 WO2016008401A1 (zh) 2014-07-15 2015-07-14 一种含多西他赛的药物组合物

Country Status (4)

Country Link
US (1) US10080720B2 (zh)
GB (1) GB2542092B (zh)
WO (1) WO2016008401A1 (zh)
ZA (1) ZA201700278B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105093795B (zh) * 2015-06-03 2017-06-16 海信集团有限公司 一种双色激光光源
EP4386074A1 (en) 2022-12-16 2024-06-19 The Procter & Gamble Company Fabric and home care composition
DE102023135175A1 (de) 2022-12-16 2024-06-27 Basf Se Verfahren zur Herstellung von Aminosäureestern und organischen Sulfonsäuresalzen sowie Aminosäureestern und deren Salzen

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
US20040197408A1 (en) * 2002-12-30 2004-10-07 Angiotech International Ag Amino acids in micelle preparation
US8124128B2 (en) * 2005-11-08 2012-02-28 Industrial Technology Research Institute Amphiphilic block copolymers and nano particles comprising the same
CN101023940A (zh) 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
WO2009084801A1 (en) * 2007-12-31 2009-07-09 Samyang Corporation Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same
PL2774608T3 (pl) * 2008-06-16 2020-05-18 Pfizer Inc. Polimerowe nanocząstki napełnione lekiem oraz sposoby ich wytwarzania i zastosowania
CN101869712B (zh) * 2009-04-21 2016-01-20 财团法人工业技术研究院 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物
EP2460539A4 (en) * 2009-07-31 2013-12-04 Xi An Libang Medical Technology Co Ltd MEDICAMENT IN THE FORM OF NANO OR MICROBALLS, METHOD FOR THE PRODUCTION THEREOF AND COMPOSITION THEREOF AND USE THEREOF
CN101972480B (zh) * 2010-01-19 2013-01-02 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
CN101787119A (zh) * 2010-03-25 2010-07-28 复旦大学 一种具有肿瘤组织pH响应性的聚合物及其胶束
CN101804021B (zh) 2010-04-21 2012-05-09 山东大学 载多烯紫杉醇纳米粒混合胶束制剂及冻干剂的制备方法
CN102218027B (zh) * 2011-04-22 2014-07-02 上海谊众生物技术有限公司 一种包载难溶性抗肿瘤药物的聚合物胶束冻干制剂
US20150017245A1 (en) * 2011-09-22 2015-01-15 Bind Therapeutics, Inc. Methods of treating cancers with therapeutic nanoparticles
CN102617843B (zh) 2012-04-09 2013-12-25 福州市台江区泽越医药技术有限公司 一种生物医用氨基酸-聚醚-聚酯三嵌段共聚物的制备
CN102885772B (zh) 2012-09-29 2013-11-20 山东大学 一种载多烯紫杉醇混合胶束制剂及其制备方法
CN103772686B (zh) * 2012-10-26 2015-01-07 苏州雷纳药物研发有限公司 一种两亲性嵌段共聚物及其制备方法、以及该共聚物与抗肿瘤药物形成的胶束载药系统
US9499667B2 (en) * 2013-04-19 2016-11-22 Gainia (Shanghai) Patent Technology Ltd. Biodegradable surfactant, preparation method and use thereof
CN104510714A (zh) * 2014-05-10 2015-04-15 上海珀理玫化学科技有限公司 一种不含赋形剂的紫杉醇冻干粉制剂及其制备方法
CN104511020A (zh) * 2014-05-10 2015-04-15 上海珀理玫化学科技有限公司 一种紫杉醇的药物组合物
CN104510716A (zh) * 2014-05-10 2015-04-15 上海珀理玫化学科技有限公司 一种含有赋形剂的紫杉醇冻干粉制剂及其制备方法
CN104511022A (zh) * 2014-05-10 2015-04-15 上海珀理玫化学科技有限公司 一种紫杉醇的药物组合物
CN104510712A (zh) * 2014-05-10 2015-04-15 上海珀理玫化学科技有限公司 一种不含赋形剂的紫杉醇冻干粉制剂及其制备方法
CN104510705A (zh) * 2014-05-10 2015-04-15 上海珀理玫化学科技有限公司 一种紫杉醇胶束制剂
CN104511021A (zh) * 2014-05-10 2015-04-15 上海珀理玫化学科技有限公司 一种不含赋形剂的紫杉醇冻干粉制剂及其制备方法
CN104510703A (zh) * 2014-05-10 2015-04-15 上海珀理玫化学科技有限公司 一种紫杉醇胶束制剂
CN109432001A (zh) * 2014-05-10 2019-03-08 上海珀理玫化学科技有限公司 紫杉醇胶束制剂的生产工艺及其制品
CN104510713A (zh) * 2014-05-10 2015-04-15 上海珀理玫化学科技有限公司 一种含有赋形剂的紫杉醇冻干粉制剂及其制备方法
CN104510715A (zh) * 2014-05-10 2015-04-15 上海珀理玫化学科技有限公司 一种含有赋形剂的紫杉醇冻干粉制剂及其制备方法
CN104511023A (zh) * 2014-05-15 2015-04-15 上海珀理玫化学科技有限公司 一种紫杉醇的药物组合物
CN104511024A (zh) * 2014-05-15 2015-04-15 上海珀理玫化学科技有限公司 一种不含赋形剂的紫杉醇冻干粉制剂及其制备方法
CN104510706A (zh) * 2014-05-15 2015-04-15 上海珀理玫化学科技有限公司 一种紫杉醇胶束制剂
CN104546740A (zh) * 2014-05-15 2015-04-29 上海珀理玫化学科技有限公司 一种含有赋形剂的紫杉醇冻干粉制剂及其制备方法

Also Published As

Publication number Publication date
GB2542092B (en) 2019-05-29
US10080720B2 (en) 2018-09-25
GB201700560D0 (en) 2017-03-01
US20170157050A1 (en) 2017-06-08
GB2542092A (en) 2017-03-08
ZA201700278B (en) 2019-06-26
WO2016008401A1 (zh) 2016-01-21

Similar Documents

Publication Publication Date Title
MX2019013218A (es) Composición oftálmica líquida estable, que comprende una solución acuosa con un tampón, un agente de tonicidad, un quelante, un modificador de la viscosidad y atropina; y el uso de la misma para el tratamiento de la miopía.
MX2020007227A (es) Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa.
EP4371616A3 (en) Compositions of obeticholic acid and methods of use
WO2014066468A8 (en) Stable, low viscosity antibody formulation
NZ709958A (en) Enhanced stability of novel liquid compositions
MX348823B (es) Formulaciones estables de linaclotida.
PH12016500793A1 (en) Turmeric extract containing soft pastilles
MY167777A (en) A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site
WO2015171460A3 (en) Formulations of cyclophosphamide liquid concentrate
RS54584B1 (en) 15-HEPE PREPARATIONS AND PROCEDURES FOR THEIR USE
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
MY173159A (en) Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer
WO2014118808A3 (en) Ticagrelor solid dispersion
WO2016008401A8 (zh) 一种含多西他赛的药物组合物
HRP20180316T1 (hr) Izolirani čvrsti oblik anamorelin monohidroklorida s niskim molarnim odnosom klorida: anamolerina i niskim sadržajem rezidualnog organskog otapala
MY185605A (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
NZ628451A (en) Dehydrated plant-derived products and methods for making the same
WO2018105941A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
GB2514741A (en) Composition for use as a paint binder
MX2015008068A (es) Unidad solida con alto contenido en fexofenadina y su procedimiento de preparacion.
AU2018255063A1 (en) Method for preparing active material nanoparticles using lipid as lubricant for milling
WO2012147101A3 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
MX2016013559A (es) Formulaciones de proteina estables que comprenden un exceso molar de sorbitol.
MX2022005317A (es) Prevencion de formacion de particulas visibles en soluciones acuosas de proteina.
AU2017251957A1 (en) Hyaluronic acid conjugates and uses thereof

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15822453

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 201700560

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20150714

WWE Wipo information: entry into national phase

Ref document number: 15325939

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15822453

Country of ref document: EP

Kind code of ref document: A1